Fortress Biotech Inc (FBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fortress Biotech Inc (FBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH135290D
  • |
  • Pages: 108
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Fortress Biotech Inc (Fortress), formerly Coronado Biosciences Inc is a biopharmaceutical company that develops and commercializes pharmaceutical and biotechnology products. The company offers products in the areas of dermatology, cancer, pain management and autoimmune diseases, among others. It offers Dermasorb HC, Luxamed wound cream and Ceracade. Fortress's products are used to treat and manage atopic dermatitis, wounds and other dermatological diseases. The company also provides funding to support their research and development programs. It markets its products in the US and abroad. Fortress is headquartered in New York, the US.

Fortress Biotech Inc (FBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Fortress Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Altamira Bio Acquires NIH License and CRADAs Relating to the Development of ManNAc from New Zealand Pharma 15

Venture Financing 16

Avenue Therapeutics Raises USD0.2 Million in Venture Financing 16

Helocyte Raises Additional USD2 Million in Venture Financing 17

Helocyte Raises USD1 Million in Venture Financing 18

Checkpoint Therapeutics Raises USD57.8 Million Venture Financing 19

Partnerships 20

Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 20

Applied BioMath Enters into Agreement with Checkpoint Therapeutics 21

Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School 22

Mustang Bio Enters into Agreement with Beth Israel Deaconess 23

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 24

Helocyte Enters into Agreement with City of Hope for PepVax 25

Helocyte Enters into Agreement with City of Hope 26

Checkpoint Therapeutics Enters into Research Agreement with NeuPharma 27

Coronado Biosciences Forms Joint Venture with City of Hope 28

TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 29

TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 30

Licensing Agreements 31

Mustang Bio Enters into Licensing Agreement with St. Jude Children's Research Hospital 31

Mustang Bio Enters into Licensing Agreement with Harvard University 32

Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 33

Mustang Bio Enters into Licensing Agreement with City of Hope 34

NICHD Enters into Licensing Agreement with Cyprium Therapeutics 35

Fortress Biotech Enters into Licensing Agreement with Columbia University 36

Cellvation Enters into Licensing Agreement with University of Texas Health Science Center at Houston 37

Fortress Biotech Enters into Licensing Agreement with Effcon Labs 38

Fortress Biotech Enters into Licensing Agreement with GeneMedicine 39

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 40

Journey Medical Enters into Licensing Agreement for Ceracade 41

Journey Medical Enters into Licensing Agreement for Luxamend 42

Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 43

Helocyte Exercises Option for Licensing Agreement with City of Hope for Pentamer 44

Mustang Bio Enters into Licensing Agreement with City of Hope 45

Helocyte Amends Agreement with City of Hope National Medical Center 46

Journey Medical Enters into Licensing Agreement for Dermatological Product 47

Fortress Biotech Amends its Licensing Agreement with NeuPharma 48

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 49

Coronado Enters Into Licensing Agreement for Product to Treat Hand-Foot Syndrome 51

Coronado Biosciences Enters into Licensing Agreement with Revogenex Ireland for IV Tramadol 52

Coronado Biosciences Enters Into Licensing Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis 53

Dr. Falk Pharma Enters Into Licensing Agreement With Coronado Biosciences For CNDO-201 54

Coronado Biosciences Enters Into Licensing Agreement With Dr. Falk Pharma For Europe Application 56

Coronado Biosciences Expands Licensing Agreement With Ovamed For Manufacturing Rights Of TSO 58

Equity Offering 59

Mustang Bio Plans to Raise up to USD75 Million in Public Offering of Securities 59

Fortress Biotech Plans to Raise up to USD50 Million in Public Offering of Shares 60

Avenue Therapeutics Plans to Raise up to USD75 Million in Public Offering of Securities 61

Checkpoint Therapeutics Prices Public Offering of Shares for USD20 Million 62

Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares 64

Fortress Biotech Prices Public Offering of Series A Preferred Shares for USD25 million 65

Avenue Therapeutics Raises USD38 Million in IPO 67

Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 69

Mustang Bio Raises USD94.5 Million in Private Placement 70

Mustang Bio Raises USD7.1 Million in Second Tranche of Private Placement of Units 71

Mustang Bio Raises USD12.4 Million in First Tranche of Private Placement of Units 72

Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units 73

Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units 74

Coronado Biosciences Raises USD3.5 Million in Private Placement of Shares 75

Coronado Biosciences Files Registration Statement For Public Offering Of Securities For USD 200 Million 76

Coronado Biosciences Announces Public Offering Of Common Stock For USD 45 Million 77

Coronado Biosciences Completes Third Tranche Of Public Offering Of Common Stock For USD 10 Million 78

Coronado Biosciences Completes Public Offering Of Shares For USD 28.8 Million 79

Debt Offering 80

Fortress Biotech Raises USD3.3 Million in Private Placement of 8% Notes Due 2020 80

Fortress Biotech Inc-Key Competitors 81

Fortress Biotech Inc-Key Employees 82

Fortress Biotech Inc-Locations And Subsidiaries 83

Head Office 83

Other Locations & Subsidiaries 83

Joint Venture 84

Recent Developments 85

Financial Announcements 85

Nov 02, 2018: Checkpoint Therapeutics reports third quarter 2018 financial results and recent corporate highlights 85

Aug 09, 2018: Fortress Biotech reports second quarter 2018 financial results and recent corporate highlights 86

May 10, 2018: Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights 88

Mar 16, 2018: Fortress Biotech Announces Fourth Quarter And Full-Year 2017 Financial Results 90

Nov 09, 2017: Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights 93

Aug 14, 2017: Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 95

Aug 09, 2017: Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights 96

May 10, 2017: Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights 98

Mar 16, 2017: Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016 100

Corporate Communications 103

Jul 03, 2017: Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics 103

Jul 03, 2017: Fortress Biotech names president and CEO of Avenue Therapeutics 104

Mar 14, 2017: Fortress Biotech Announces Appointment of Lung S. Yam, M.D., Ph.D., Named Cyprium Chief Executive Officer 105

Jan 04, 2017: Fortress Biotech announce the appointment of Michael Spector as Caelum's Chief Executive Officer. 106

Appendix 107

Methodology 107

About GlobalData 107

Contact Us 107

Disclaimer 107

List of Figures

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

List of Tables

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Fortress Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Fortress Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Altamira Bio Acquires NIH License and CRADAs Relating to the Development of ManNAc from New Zealand Pharma 16

Avenue Therapeutics Raises USD0.2 Million in Venture Financing 17

Helocyte Raises Additional USD2 Million in Venture Financing 18

Helocyte Raises USD1 Million in Venture Financing 19

Checkpoint Therapeutics Raises USD57.8 Million Venture Financing 20

Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 21

Applied BioMath Enters into Agreement with Checkpoint Therapeutics 22

Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School 23

Mustang Bio Enters into Agreement with Beth Israel Deaconess 24

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 25

Helocyte Enters into Agreement with City of Hope for PepVax 26

Helocyte Enters into Agreement with City of Hope 27

Checkpoint Therapeutics Enters into Research Agreement with NeuPharma 28

Coronado Biosciences Forms Joint Venture with City of Hope 29

TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics 30

TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies 31

Mustang Bio Enters into Licensing Agreement with St. Jude Children's Research Hospital 32

Mustang Bio Enters into Licensing Agreement with Harvard University 33

Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 34

Mustang Bio Enters into Licensing Agreement with City of Hope 35

NICHD Enters into Licensing Agreement with Cyprium Therapeutics 36

Fortress Biotech Enters into Licensing Agreement with Columbia University 37

Cellvation Enters into Licensing Agreement with University of Texas Health Science Center at Houston 38

Fortress Biotech Enters into Licensing Agreement with Effcon Labs 39

Fortress Biotech Enters into Licensing Agreement with GeneMedicine 40

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 41

Journey Medical Enters into Licensing Agreement for Ceracade 42

Journey Medical Enters into Licensing Agreement for Luxamend 43

Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 44

Helocyte Exercises Option for Licensing Agreement with City of Hope for Pentamer 45

Mustang Bio Enters into Licensing Agreement with City of Hope 46

Helocyte Amends Agreement with City of Hope National Medical Center 47

Journey Medical Enters into Licensing Agreement for Dermatological Product 48

Fortress Biotech Amends its Licensing Agreement with NeuPharma 49

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute 50

Coronado Enters Into Licensing Agreement for Product to Treat Hand-Foot Syndrome 52

Coronado Biosciences Enters into Licensing Agreement with Revogenex Ireland for IV Tramadol 53

Coronado Biosciences Enters Into Licensing Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis 54

Dr. Falk Pharma Enters Into Licensing Agreement With Coronado Biosciences For CNDO-201 55

Coronado Biosciences Enters Into Licensing Agreement With Dr. Falk Pharma For Europe Application 57

Coronado Biosciences Expands Licensing Agreement With Ovamed For Manufacturing Rights Of TSO 59

Mustang Bio Plans to Raise up to USD75 Million in Public Offering of Securities 60

Fortress Biotech Plans to Raise up to USD50 Million in Public Offering of Shares 61

Avenue Therapeutics Plans to Raise up to USD75 Million in Public Offering of Securities 62

Checkpoint Therapeutics Prices Public Offering of Shares for USD20 Million 63

Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares 65

Fortress Biotech Prices Public Offering of Series A Preferred Shares for USD25 million 66

Avenue Therapeutics Raises USD38 Million in IPO 68

Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 70

Mustang Bio Raises USD94.5 Million in Private Placement 71

Mustang Bio Raises USD7.1 Million in Second Tranche of Private Placement of Units 72

Mustang Bio Raises USD12.4 Million in First Tranche of Private Placement of Units 73

Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units 74

Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units 75

Coronado Biosciences Raises USD3.5 Million in Private Placement of Shares 76

Coronado Biosciences Files Registration Statement For Public Offering Of Securities For USD 200 Million 77

Coronado Biosciences Announces Public Offering Of Common Stock For USD 45 Million 78

Coronado Biosciences Completes Third Tranche Of Public Offering Of Common Stock For USD 10 Million 79

Coronado Biosciences Completes Public Offering Of Shares For USD 28.8 Million 80

Fortress Biotech Raises USD3.3 Million in Private Placement of 8% Notes Due 2020 81

Fortress Biotech Inc, Key Competitors 82

Fortress Biotech Inc, Key Employees 83

Fortress Biotech Inc, Other Locations 84

Fortress Biotech Inc, Subsidiaries 84

Fortress Biotech Inc, Joint Venture 85

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Fortress Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17773
Site License
USD 500 INR 35545
Corporate User License
USD 750 INR 53318

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com